Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using AG真人官方-World Data for External Control Arms
Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.
The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the AG真人官方-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.
The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.
Onco-Innovations Limited (OTCQB:ONNVF) ha annunciato che la sua controllata Inka Health 猫 stata scelta da OneMedNet (Nasdaq:ONMD) per guidare un'iniziativa di analisi dati oncologici basata sull'intelligenza artificiale. Il progetto mira a sviluppare bracci di controllo esterni (ECA) utilizzando i dati paziente di qualit脿 regolatoria di OneMedNet per accelerare lo sviluppo di terapie oncologiche.
La collaborazione sfrutter脿 la piattaforma SynoGraph di Inka Health per convalidare un ECA per lo studio Keynote-189 sul pembrolizumab nel carcinoma polmonare non a piccole cellule. Questa iniziativa si rivolge al mercato delle Evidenze dal Mondo AG真人官方e (RWE), che si prevede raggiunger脿 un valore di 4,6 miliardi di dollari entro il 2030. L'obiettivo 猫 dimostrare come i dati real-world possano replicare i risultati degli studi clinici tradizionali in modo pi霉 efficiente, riducendo potenzialmente costi e tempi di sviluppo.
Le aziende intendono presentare i risultati a ISPOR Europe 2025, posizionandosi all'avanguardia nella ricerca oncologica e nello sviluppo farmaceutico guidati dall'intelligenza artificiale.
Onco-Innovations Limited (OTCQB:ONNVF) anunci贸 que su subsidiaria Inka Health ha sido seleccionada por OneMedNet (Nasdaq:ONMD) para liderar una iniciativa de an谩lisis de datos oncol贸gicos impulsada por IA. El proyecto busca desarrollar brazos de control externos (ECA) utilizando datos de pacientes con calidad regulatoria de OneMedNet para acelerar el desarrollo de terapias contra el c谩ncer.
La colaboraci贸n utilizar谩 la plataforma SynoGraph de Inka Health para validar un ECA para el ensayo Keynote-189 de pembrolizumab en c谩ncer de pulm贸n no microc铆tico. Esta iniciativa apunta al mercado de Evidencia del Mundo AG真人官方 (RWE), proyectado a alcanzar $4.6 mil millones para 2030. El objetivo es demostrar c贸mo los datos del mundo real pueden replicar los resultados de ensayos cl铆nicos tradicionales de manera m谩s eficiente, reduciendo potencialmente costos y tiempos de desarrollo.
Las compa帽铆as planean presentar sus hallazgos en ISPOR Europe 2025, posicion谩ndose como l铆deres en investigaci贸n oncol贸gica y desarrollo de medicamentos impulsados por IA.
Onco-Innovations Limited (OTCQB:ONNVF)電� 鞛愴殞靷� Inka Health臧赌 OneMedNet (Nasdaq:ONMD)鞐� 鞚橅暣 AI 旮半皹 膦呾枒頃� 雿办澊韯� 攵勳劃 頂勲鞝濏姼毳� 欤茧弰頃� 鞐呾泊搿� 靹犾爼霅橃棃雼り碃 氚滍憸頄堨姷雼堧嫟. 鞚� 頂勲鞝濏姼電� OneMedNet鞚� 攴滌牅 霌标笁 頇橃瀽 雿办澊韯半ゼ 頇滌毄頃橃棳 鞕鸽秬 雽�臁瓣蛋(ECAs)鞚� 臧滊皽頃� 鞎� 旃橂鞝� 臧滊皽鞚� 臧赌靻嶍檾頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞚措矆 順戨牓鞚� Inka Health鞚� SynoGraph 頂岆灚韽�鞚� 頇滌毄頃� 牍勳唽靹疙彫韽愳晹鞐� 雽�頃� 韼笇搿るΜ欤茧 Keynote-189 鞛勳儊鞁滍棙鞚� ECA毳� 瓴�歃濏暊 鞓堨爼鞛呺媹雼�. 鞚� 鞚措媹靺旐嫲敫岆姅 鞁れ牅 靹戈硠 攴缄卑(RWE) 鞁滌灔毳� 瓴儱頃橂┌, 2030雲勱箤歆� 46鞏� 雼煬鞐� 鞚措ゼ 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 頂勲鞝濏姼電� 鞁れ牅 靹戈硠 雿办澊韯半ゼ 韱淀暣 鞝勴喌鞝� 鞛勳儊鞁滍棙 瓴瓣臣毳� 氤措嫟 須湪鞝侅溂搿� 鞛槃頃溂搿滌崹 臧滊皽 牍勳毄瓿� 旮瓣皠鞚� 欷勳澊電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
巩戩偓电� ISPOR Europe 2025鞐� 鞐瓣惮 瓴瓣臣毳� 鞝滌稖頃� 瓿勴殟鞚措┌, AI 旮半皹 膦呾枒頃� 鞐瓣惮 氚� 鞁犾暯 臧滊皽鞚� 靹犽憪鞐� 靹滊姅 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Onco-Innovations Limited (OTCQB:ONNVF) a annonc茅 que sa filiale Inka Health a 茅t茅 choisie par OneMedNet (Nasdaq:ONMD) pour diriger une initiative d'analyse de donn茅es oncologiques bas茅e sur l'intelligence artificielle. Le projet vise 脿 d茅velopper des bras de contr么le externes (ECA) en utilisant les donn茅es patients de qualit茅 r茅glementaire de OneMedNet afin d'acc茅l茅rer le d茅veloppement des th茅rapies contre le cancer.
La collaboration utilisera la plateforme SynoGraph d'Inka Health pour valider un ECA pour l'essai Keynote-189 du pembrolizumab dans le cancer du poumon non 脿 petites cellules. Cette initiative cible le march茅 des preuves du monde r茅el (RWE), dont la valeur devrait atteindre 4,6 milliards de dollars d'ici 2030. Le projet a pour but de d茅montrer comment les donn茅es du monde r茅el peuvent reproduire plus efficacement les r茅sultats des essais cliniques traditionnels, r茅duisant potentiellement les co没ts et les d茅lais de d茅veloppement.
Les entreprises pr茅voient de pr茅senter leurs r茅sultats 脿 ISPOR Europe 2025, se positionnant ainsi 脿 la pointe de la recherche oncologique et du d茅veloppement pharmaceutique pilot茅s par l'IA.
Onco-Innovations Limited (OTCQB:ONNVF) gab bekannt, dass seine Tochtergesellschaft Inka Health von OneMedNet (Nasdaq:ONMD) ausgew盲hlt wurde, eine KI-gesteuerte Initiative zur Onkologie-Datenanalyse zu leiten. Das Projekt zielt darauf ab, externe Kontrollarme (ECAs) mithilfe von OneMedNets regulatorisch gepr眉ften Patientendaten zu entwickeln, um die Entwicklung von Krebstherapien zu beschleunigen.
Die Zusammenarbeit wird die SynoGraph-Plattform von Inka Health nutzen, um einen ECA f眉r die Keynote-189-Studie mit Pembrolizumab bei nicht-kleinzelligem Lungenkrebs zu validieren. Diese Initiative richtet sich an den AG真人官方-World Evidence (RWE)-Markt, der bis 2030 voraussichtlich 4,6 Milliarden US-Dollar erreichen wird. Ziel ist es, aufzuzeigen, wie AG真人官方-World-Daten traditionelle klinische Studien effizienter replizieren k枚nnen, was potenziell Entwicklungszeit und -kosten reduziert.
Die Unternehmen planen, ihre Ergebnisse auf der ISPOR Europe 2025 vorzustellen und sich damit an der Spitze der KI-gesteuerten onkologischen Forschung und Arzneimittelentwicklung zu positionieren.
- Partnership with Nasdaq-listed OneMedNet expands presence in $4.6B AG真人官方-World Evidence market
- Potential to reduce clinical trial costs and accelerate cancer therapy development through AI-driven analytics
- Access to regulatory-grade patient data for external control arm development
- Strategic positioning in emerging healthcare technology sector
- Project success and regulatory acceptance of external control arms not guaranteed
- Initial focus limited to single cancer type (non-small cell lung cancer)
Insights
Inka Health's AI partnership with OneMedNet could revolutionize cancer drug development by using real-world data instead of traditional control groups.
This partnership between Inka Health (owned by Onco-Innovations) and OneMedNet represents a potentially significant advancement in clinical trial methodology for oncology. The collaboration aims to leverage OneMedNet's regulatory-grade patient data to develop external control arms (ECAs) - an alternative to traditional randomized controlled trials that could substantially reduce both time and costs in cancer drug development.
What makes this particularly noteworthy is the application of Inka's SynoGraph platform, which combines machine learning with causal inference methods to build and validate ECAs. They're targeting the Keynote-189 trial of pembrolizumab in non-small cell lung cancer (NSCLC) as their initial proof-of-concept. This is methodologically sound as NSCLC has sufficient data volume and clinical significance to demonstrate value.
From a data science perspective, the regulatory alignment they're pursuing with FDA, EMA, and NICE guidelines is crucial - external control arms face significant validation hurdles and regulatory scrutiny. The real value proposition hinges on whether their approach can genuinely replicate traditional clinical trial results with sufficient rigor to satisfy regulatory requirements.
This partnership taps into the growing $4.6 billion real-world evidence (RWE) market. If successful, this approach could significantly accelerate cancer therapy approvals while reducing the ethical concerns of placing patients in control arms where they receive placebos or standard-of-care treatments rather than potentially life-saving experimental therapies. The planned scientific abstract submission to ISPOR Europe 2025 will be an important validation milestone for this methodology.
This partnership represents a strategic move in the rapidly evolving landscape of pharmaceutical R&D, where real-world data (RWD) is increasingly valued for regulatory submissions. The traditional clinical trial paradigm - randomizing patients to treatment or control arms - is often the most expensive and time-consuming aspect of drug development, particularly in oncology where patient recruitment is challenging.
Inka Health's approach using OneMedNet's data to create external control arms (ECAs) could potentially address several critical industry pain points:
- Reducing the $2.6 billion average cost of bringing a new drug to market
- Shortening the typical 7-10 year development timeline
- Allowing more patients to receive experimental treatments rather than control interventions
- Enabling trials in rare cancers where control arms are particularly difficult to populate
The decision to focus on replicating the Keynote-189 trial for pembrolizumab (Keytruda) in NSCLC is strategically sound. Keytruda is Merck's blockbuster immunotherapy with over $20 billion in annual sales, and this approach creates a visible proof-of-concept with a well-documented existing trial.
The regulatory landscape has been increasingly receptive to RWD/RWE approaches. The FDA's 2018 framework for RWE and the 21st Century Cures Act have opened doors for alternative evidence generation. However, the bar remains high for acceptance of external control arms as primary evidence.
If Inka and OneMedNet can demonstrate their approach meets regulatory standards, this could position both companies as leaders in a transformative approach to clinical development, potentially attracting partnerships with major pharmaceutical companies seeking to optimize their R&D investments.
Reduce development timelines and costs, while improving access to life-saving treatments
VANCOUVER, BC / / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), has been selected by OneMedNet Corporation (Nasdaq:ONMD) to lead a high-impact data analytics initiative focused on improving how cancer therapies are brought to market. The project focuses on leveraging OneMedNet's regulatory-grade patient data including Radiology Imaging data to develop external control arms (ECAs), which has the potential to be a faster, more cost-effective alternative to traditional clinical trials. This approach offers a potentially smarter way to generate clinical evidence by leveraging existing patient data, thereby possibly accelerating treatment access and reducing the need for costly, time-consuming trials. The initiative also provides both organizations with exposure to the rapidly expanding AG真人官方-World Evidence (RWE) market is projected to exceed
This strategic project reflects growing momentum behind real-world data (RWD) as a critical component of next-generation evidence generation for cancer therapeutics2. OneMedNet's iRWDTM AG真人官方-World Data platform and federated provider network offers regulatory-grade, diverse, and longitudinal datasets, making it uniquely suited to drive AG真人官方-World Evidence (RWE) studies and accelerate healthcare innovation.
The multi-phase project is intended to showcase how OneMedNet's oncology dataset can be used to replicate the results of traditional clinical trials, without the same time, cost, and complexity as traditional trials. By offering a faster and more efficient path to generate the evidence needed for regulatory and reimbursement approvals, this initiative can potentially help accelerate market entry for new cancer therapies, particularly in areas of high unmet needs like colorectal cancer.
Inka Health plans to deploy its proprietary SynoGraph platform, which combines machine learning with causal inference methods, to build and validate an ECA for the Keynote-189 trial3 of pembrolizumab in non-small cell lung cancer aligned with regulatory and Health Technology Assessment (HTA) best practices, including those from the FDA, European Medicines Agency (EMA), and National Institute for Health and Care Excellence (NICE). The initial focus will be on non-small cell lung cancer (NSCLC), a prevalent and clinically significant cancer type where real-world insights can meaningfully improve both patient access to therapies and regulatory confidence.
We selected Inka Health for this initiative because their methodological approach aligns perfectly with our vision for high-quality evidence generation," said Aaron Green, President & CEO of OneMedNet. "Their ability to apply rigorous, AI-driven analytics to our regulatory-grade, diverse datasets makes them the ideal partner to showcase how OneMedNet's AG真人官方-World Data can be used as a trusted external control arm in oncology research-with the potential to help pharmaceutical companies realize a stronger ROI on clinical development and driving broader adoption among CROs and life sciences organizations looking for faster, more cost-effective trial alternatives.
The collaboration is expected to result in a scientific abstract for submission to ISPOR Europe 2025, reinforcing Inka Health's leadership in applying artificial intelligence and real-world data to oncology research. As ECAs become increasingly prominent in global drug development strategies, this project positions Onco and its subsidiary at the forefront of how industry brings new therapies to patients.
"This collaboration is about more than applying advanced analytics to oncology data. It's about reshaping how we generate credible evidence for regulatory and reimbursement decisions using real-world patients, not just trial participants. With SynoGraph, we're aiming to set a new bar for how external control arms can be built and trusted." said Paul Arora, Co-Founder of Inka Health.
Furthermore, the Company announces, further to its news releases dated May 26, 2025 and March 25, 2025, that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: [email protected]; telephone: +491772481220; and website: ) ("MCS") for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the "Services"). The Services are expected to run until October 30, or until budget exhaustion. The Company has paid MCS EUR 250,000 for the extended term. No securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising.
About OneMedNet
OneMedNet is revolutionizing how the world unlocks AG真人官方-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD鈩� platform. This isn't just data, it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities, rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at .
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's ability to collaborate successfully with OneMedNet, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including, but not limited to, the inability of Inka or the Company to collaborate successfully with OneMedNet. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
1 AG真人官方 World Evidence Solutions Market -
2 Wang X, Dormont F, Lorenzato C, et al. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021. J Cancer Policy. 2023;35:100403.
3
SOURCE: Onco-Innovations Limited
View the original on ACCESS Newswire
FAQ
What is the partnership between Inka Health and OneMedNet (ONNVF) about?
How will ONNVF's SynoGraph platform be used in the OneMedNet collaboration?
What is the market potential for AG真人官方-World Evidence that ONNVF is targeting?
How does ONNVF's external control arm approach benefit cancer drug development?
When will results from ONNVF's oncology data analytics project be presented?
